37. 膿疱性乾癬（汎発型） Generalised pustular psoriasis Clinical trials / Disease details

臨床試験数 : 79 / 薬物数 : 57 - (DrugBank : 21) / 標的遺伝子数 : 20 - 標的パスウェイ数 : 102

9 trials found

diseases per page:

Showing 1 to 9 of 9 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05366855 (ClinicalTrials.gov)	April 21, 2022	25/4/2022	Long-Term Safety and Efficacy of Imsidolimab (ANB019) in Subjects With Generalized Pustular Psoriasi ...	A Phase 3, Long-Term Extension Study to Evaluate the Safety and Efficacy of Imsidolimab (ANB019) in ...	Generalized Pustular Psoriasis	Biological: Imsidolimab;Other: Placebo	AnaptysBio, Inc.	NULL	Recruiting	18 Years	80 Years	All	45	Phase 3	United States;Australia;France;Georgia;Germany;Korea, Republic of;Malaysia;Morocco;Poland;Romania;Sp ...
2	NCT05352893 (ClinicalTrials.gov)	April 14, 2022	25/4/2022	Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With ...	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ...	Generalized Pustular Psoriasis	Drug: Imsidolimab high dose;Drug: Imsidolimab low dose;Other: Placebo	AnaptysBio, Inc.	NULL	Recruiting	18 Years	80 Years	All	45	Phase 3	United States;Australia;Georgia;Germany;Korea, Republic of;Malaysia;Morocco;Poland;Romania;Slovakia; ...
3	EUCTR2021-001447-27-ES (EUCTR)	07/02/2022	12/11/2021	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ...	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ...	Subjects with generalized pustular psoriasis MedDRA version: 20.0;Level: PT;Classification code 1003 ...	Product Code: ANB019 INN or Proposed INN: anti-IL-36R monoclonal antibody	AnaptysBio Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	45	Phase 3	Taiwan;Thailand;Malaysia;Spain;Australia;Georgia;Germany;Korea, Republic of
4	EUCTR2021-001448-90-FR (EUCTR)	02/02/2022	05/10/2021	A Phase 3, Long-Term Extension Study to Evaluate the Safety and Efficacy of Imsidolimab (ANB019) in ...	A Phase 3, Long-Term Extension Study to Evaluate the Safety and Efficacy of Imsidolimab (ANB019) in ...	Subjects with generalized pustular psoriasis MedDRA version: 20.0;Level: PT;Classification code 1003 ...	Product Code: ANB019 INN or Proposed INN: anti-IL-36R monoclonal antibody	AnaptysBio Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	45	Phase 3	France;Taiwan;Spain;Malaysia;Thailand;Australia;Georgia;Germany;Korea, Republic of
5	EUCTR2021-001448-90-ES (EUCTR)	21/01/2022	19/10/2021	A Phase 3, Long-Term Extension Study to Evaluate the Safety and Efficacy of Imsidolimab (ANB019) in ...	A Phase 3, Long-Term Extension Study to Evaluate the Safety and Efficacy of Imsidolimab (ANB019) in ...	Subjects with generalized pustular psoriasis MedDRA version: 20.0;Level: PT;Classification code 1003 ...	Product Code: ANB019 INN or Proposed INN: anti-IL-36R monoclonal antibody	AnaptysBio Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	45	Phase 3	Taiwan;Thailand;Malaysia;Spain;Australia;Georgia;Germany;Korea, Republic of
6	EUCTR2021-001447-27-DE (EUCTR)	08/12/2021	08/09/2021	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ...	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ...	Subjects with generalized pustular psoriasis MedDRA version: 20.0;Level: PT;Classification code 1003 ...	Product Code: ANB019 INN or Proposed INN: anti-IL-36R monoclonal antibody Product Code: ANB019 INN or P ...	AnaptysBio Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	45	Phase 3	Georgia;Germany;United States;Taiwan;Spain;Thailand;United Kingdom;France;Malaysia;Poland;Romania;Au ...
7	EUCTR2021-001448-90-DE (EUCTR)	08/12/2021	08/09/2021	A Phase 3, Long-Term Extension Study to Evaluate the Safety and Efficacy of Imsidolimab (ANB019) in ...	A Phase 3, Long-Term Extension Study to Evaluate the Safety and Efficacy of Imsidolimab (ANB019) in ...	Subjects with generalized pustular psoriasis MedDRA version: 20.0;Level: PT;Classification code 1003 ...	Product Code: ANB019 INN or Proposed INN: anti-IL-36R monoclonal antibody Product Code: ANB019 INN or P ...	AnaptysBio Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	45	Phase 3	United States;Taiwan;Spain;Thailand;United Kingdom;France;Malaysia;Poland;Romania;Australia;Georgia; ...
8	NCT03619902 (ClinicalTrials.gov)	March 4, 2019	19/7/2018	A Study to Evaluate the Efficacy and Safety of ANB019in Subjects With Generalized Pustular Psoriasis ...	A Single Arm Multiple Dose Study to Assess the Efficacy and Safety of ANB019in Subjects With General ...	Generalized Pustular Psoriasis	Drug: ANB019	AnaptysBio, Inc.	NULL	Completed	18 Years	75 Years	All	8	Phase 2	United States;Korea, Republic of;Poland;United Kingdom
9	EUCTR2017-004021-33-GB (EUCTR)	04/05/2018	20/12/2017	To Assess the Efficacy and Safety of ANB019 in Subjects with Generalized Pustular Psoriasis	A Single Arm Multiple Dose Study to Assess the Efficacy and Safety of ANB019in Subjects with General ...	Generalized Pustular Psoriasis (GPP) MedDRA version: 21.0;Level: LLT;Classification code 10037159;Te ...	Product Code: ANB019 INN or Proposed INN: anti-IL-36R monoclonal antibody Other descriptive name: Alva ...	AnaptysBio Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	10	Phase 2	United States;United Kingdom

First Previous1Next Last